Patricia Paulhus
Nurse Practitioner · Hemet, CANPI 1326310640
Payments from drug & device makers
Across 209 payments — averaging $26.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$935
- AstraZeneca$877
- Vifor Pharma, Inc.$816
- Akebia Therapeutics Inc$673
- Ardelyx, Inc.$546
- Fresenius USA Marketing, Inc.$303
- plus $1K from 15 others
What the payments were for
- Food & beverage$5,44399%
- Education$661%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 28 | $935 |
| AstraZeneca(2 entities) | 35 | $877 |
| Vifor Pharma, Inc. | 29 | $816 |
| Akebia Therapeutics Inc | 23 | $673 |
| Ardelyx, Inc. | 15 | $546 |
| Fresenius USA Marketing, Inc. | 15 | $303 |
| GSK | 9 | $278 |
| Otsuka America Pharmaceutical, Inc. | 6 | $196 |
| Boehringer Ingelheim | 6 | $162 |
| Aurinia Pharma U.S., Inc. | 7 | $129 |
| Novo Nordisk | 6 | $120 |
| Calliditas Therapeutics US Inc. | 4 | $98 |
| Novartis | 4 | $75 |
| Bayer | 4 | $72 |
| Nxstage Medical, Inc. | 2 | $67 |
| Boston Scientific | 2 | $46 |
| Bard Peripheral Vascular, Inc. | 2 | $30 |
| Medtronic | 2 | $28 |
| Ultragenyx Pharmaceutical Inc. | 1 | $23 |
| Travere Therapeutics, Inc. | 8 | $18 |
| OPKO Pharmaceuticals, LLC | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,509 in reported general payments places this provider in the 95th percentile of 6,779 nurse practitioner providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XphozahTenapanor Hcl | 79 | $232,616 |
| VelphoroSucroferric Oxyhydroxide | 20 | $132,529 |
| AuryxiaFerric Citrate | 67 | $103,469 |
| VeltassaPatiromer Calcium Sorbitex | 76 | $72,544 |
| Sevelamer Carbonate | 177 | $52,518 |
| LokelmaSodium Zirconium Cyclosilicate | 45 | $42,585 |
| Calcium Acetate | 168 | $27,319 |
| ClinolipidFat Emulsion/Olive/Soy/Phospho | 89 | $25,721 |
| ProsolParenteral Amino Acid 20% No.1 | 149 | $22,318 |
| Lanthanum Carbonate | 26 | $18,305 |
| EliquisApixaban | 13 | $14,476 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 11 | $5,102 |
| ClinisolParenteral Amino Acid 15% No.5 | 23 | $3,592 |
| Nifedipine ErNifedipine | 63 | $3,534 |
| Midodrine Hcl | 61 | $2,999 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Fresenius USA Marketing, Inc.Velphoro | $303 | $132,52920 claims |
| Akebia Therapeutics IncAuryxia | $673 | $103,46967 claims |
| AstraZenecaLokelma | $877 | $42,58545 claims |
| Boehringer IngelheimStiolto Respimat | $162 | $5,10211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,779 nurse practitioner providers in California.
Other nurse practitioner in Hemet
- Rhonda HewittStanford$917K
- Linda TrinhIrvine$899K
- Denise SinagaNorthridge$728K
- Debbie TaySanta Monica$642K
- Joe GorelickCampbell$638K
- Lynsey LakinArcadia$540K
- Kelly ChoiRancho Cucamonga$483K
- Hamta ZareStanford$428K
- Shawna ChrismanRoseville$425K
- Angelina CollinsSan Diego$356K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.